Apalutamide is indicated for:
Population group: men, only adults (18 years old or older)
Apalutamide is indicated in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: men, only adults (18 years old or older)
Apalutamide is indicated in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Apalutamide is contraindicated in the following cases: